OnCo
technologiesTechnologyEstablished

Closed automated cell-therapy manufacturing

Sealed, robot-run machines that turn a patient's blood cells into a CAR-T product with far fewer hands, clean rooms, and mistakes.

Functionally closed, GMP-in-a-box platforms (Miltenyi CliniMACS Prodigy, Lonza Cocoon, Cellares Cell Shuttle, Cytiva Sefia) integrate cell selection, activation, transduction, expansion, and harvest in single-use cassettes. They cut labour and clean-room grade requirements, shorten vein-to-vein time, and are the prerequisite for point-of-care and decentralised manufacturing. Throughput per unit and comparability across sites remain the constraints.

Generic schematic · not to scale · placeholder for the cell therapy front
T cell + CAR transgene · CAR binds antigen (no MHC needed) · Tumour cell

How it works

Single-use fluid paths with integrated centrifugation, magnetic selection, incubation, and sensors; process recipes run automatically and log every step for batch release.

Strengths
  • Fewer open manipulations and contamination events
  • Lower clean-room grade needed
  • Reproducible, software-logged processes
Limitations
  • Capital cost per unit
  • Process comparability when moving between platforms
  • Still 7-14 days of culture for most products

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Closed automated cell-therapy manufacturing" OR ABSTRACT:"Closed automated cell-therapy manufacturing") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Closed automated cell-therapy manufacturing, not a curated reading list.

Connected

11top